Back to Search
Start Over
A comprehensive study of pharmaceutics solubility in supercritical solvent through diverse thermodynamic and hybrid Machine learning approaches.
- Source :
-
International journal of pharmaceutics [Int J Pharm] 2024 Oct 25; Vol. 664, pp. 124579. Date of Electronic Publication: 2024 Aug 11. - Publication Year :
- 2024
-
Abstract
- The pharmaceutical industry is increasingly drawn to the research of innovative drug delivery systems through the use of supercritical CO <subscript>2</subscript> (scCO <subscript>2</subscript> )-based techniques. Measuring the solubility of drugs in scCO <subscript>2</subscript> at varying conditions is a crucial parameter in this context. In this research, the supercritical solubility of two pharmaceutical ingredients, namely Febuxostat and Chlorpromazine, has been assessed theoretically using various thermodynamic approaches, including PR, SRK, UNIQUAC, and Wilson models. Additionally, hybrid machine learning models of PO-GPR, and PO-KNN were applied to anticipate the supercritical solubility of these medicines. Verification of the accuracy of each model for each pharmaceutical substance is conducted against previously reported experimental solubility data. In the comparison between the SRK and PR models, it is observed that the SRK model displays greater precision in correlating the solubility of both drugs. It consistently achieves a mean R <subscript>adj</subscript> value of 0.995 across all cases and mean AARD% values of 14.47 and 9.30 for Febuxostat and Chlorpromazine, respectively. Furthermore, the findings indicate that the UNIQUAC model surpasses the Wilson model in precisely representing the solubility of both medicines. It consistently achieves a mean R <subscript>adj</subscript> value higher than 0.985 across both cases and mean AARD% values of 11.39 and 7.08 for Febuxostat and Chlorpromazine, respectively. Additionally, the performance of both hybrid machine learning models proved to be excellent in anticipating the supercritical solubility of both compounds.<br />Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (Copyright © 2024 Elsevier B.V. All rights reserved.)
Details
- Language :
- English
- ISSN :
- 1873-3476
- Volume :
- 664
- Database :
- MEDLINE
- Journal :
- International journal of pharmaceutics
- Publication Type :
- Academic Journal
- Accession number :
- 39137821
- Full Text :
- https://doi.org/10.1016/j.ijpharm.2024.124579